Really enjoyed the conversation with @DWeisburd! Always fun talking about building companies!. #innovation #ai @averincapital #sustainability #Health #Startups.

Congrats to the @freenome team for their recent publication in JAMA on their pivotal study. #liquidbiopsy #ai #futureofhealth #innovation @averincapital.

I’ve always fascinated with the bias against the transformative power of technology in drug discovery.

Looking forward to hosting the webinar "Activated Intelligence: AI's Leap from Algorithms to Impact" next week with Andrew Hopkins of Xyme, Jared Saul of .@awscloud, and Andrew Dobry of BiOptic. #ai #innovation #futureofmedicine @averincapital

Great article by @BenTomaszewski on employer sponsored health benefits. With costs as a clear catalyst, the move towards integrated care and AI-driven efficiencies has the potential to deliver better outcomes for patients with less financial burden.

Per the WSJ today: 90% of drugs are generics with thin margins. Reform requires innovation in the middle of the pharmaceutical supply chain. This is an area where AI can lead to step function changes and ideally better outcomes for patients while continuing to foster the.

Great article by Averin's Eric Berry on digital twins. As we think about the need to make clinical trials faster, less expensive, and more predictable, digital twins offer a the potential for a step function change in addition to the rest of what they can do for healthcare.

Great article by Rich Yang of Biolinq on the potential for devices coupled to drugs to transform care. We are just at the beginning of the era of measured self and the potential to unlock better care and outcomes-including from what drugs would do independently.

Whenever there is a challenge presented, I prefer to think about what are the opportunities that are created. The impact of the MFN is of course far reaching, but it also strikes me that this could be huge catalyst AI drug discovery and development. Increasing productivity by.

It was great to join Frank Nestle on @bios_community to talk about the growing role of AI in bio.

RT @microbiologic: Today @SeresTx marked an important milestone in the development of drugs that leverage millions of years of coevolution….

RT @ValoHealth: Today we announced that @ValoHealth is participating at upcoming events this month and next. Will we see you there? https:/….

At @ValoHealth , we are driven to make better drugs faster - not just for ourselves to but to enable others. We are proud to enable @PioneeringMeds through Logica, a joint offering with @CharlesRiverLa1 .

Speaking with @FlagshipPioneer during #jpm2023--I'm always inspired by the great work the team @ValoHealth does in pioneering a new frontier for drug discovery and development

It was great joining @NYSE for their The Cure(ious) series during #jpm2023. I credit Bob Langer with the quote below, which has been a driver for me especially as in thinking about companies like @ValoHealth and our aspirations to make better drugs for patients, faster.

RT @ValoHealth: Valo's CEO & Founder @DavidBerry26 is presenting at the @jpmorgan Healthcare Conference on Tuesday, January 10th at 2:30 PM….

By including the capabilities of Forma Therapeutics with @ValoHealth's Opal Computational Platform, where the power of AI can enable accelerated learning, we created closed loop drug design capabilities now part of our Logica offering with Charles River Labs.

Congratulations to Frank Lee and Forma Therapeutics on their accounted acquisition by Novo Nordisk! When we @ValoHealth acquired the R&D capabilities of Forma, we saw the power to make distinctive drugs like etavopivat.

When doctors graduate from medical school they take an oath to do no harm. What isn’t spoken about is that harm can be active and it can be passive.

It's times like this where it is important to remember why we all joined the #biotech industry. It is because we want to see change. We want to deliver better options to patients and their families. Whether inflation, down markets, or beyond, that drive persists.